Pharm (TB / Anemia / Immunomodulation) Flashcards
3 Principles of [TB / NTM] tx
MID
- MultiDrug Therapy should be used: Enhances response rate and [DEC Resistance]
- INC Tx Adherence: [use short therapy course] & [DOT: Direct Observed therapy]
- Duration of tx: needs to be adequate to ensure INC cure and [DEC relapse]
Isoniazid
A: Clinical Use
B: MOA
C: Static or Cidal?
A: [1st Line Tx for ACTIVE Pulmonary TB used in combination with 2 other active drugs]
B: Prodrug; activated by [TB katG-catalase peroxidase] and targets [inhA gene product] โ> [DEC Cell Wall Mycolic Acid]
(mutations in any of these genes โ> TB Resistance to tx)
C: [Cidal for replicating organisms] / [Static for resting organisms]
Rifampin
A1: Disclaimer for this drug
A2: 2 exceptions to the Disclaimer
B: MOA
C: Contraindications (4)
A: Can NOT be used alone as an abx b/c of rapid resistance development
A2: LTBI (Latent TB infection) or [meningitis px]
B: Inhibits [rpoB gene] โ> Inhibits [DNA-dependent RNA polymerase]
C: Interacts with >100 drugs but specifically [Accelerates clearance and DEC effectiveness of CAAE:
- Coumadin
- Estrogen
- Anticonvulsants
- AntiRetroviral drgus
Ethambutol
A: Toxicity
B: Clinical use
A:
- Optic Neuritis
- Peripheral Neuropathy (less common)
B: [1st Line โhelperโ TB therapy] - helps other drugs
PyraZinAmide
A1: Clinical Use
A2: single or combination tx
B: MOA
C: Toxicity
D: Good or Poor Distribution?
A1: [TB Drug for 1st two months of therapy only]
A2: Combination
B: Prodrug; activated by [TB pyrazinamidase thtโs encoded by [pncA]
C: Hepatitis
D: Good Distribution; especially in CSF
A: Describe [1ยฐ Resistance] vs. [2ยฐ Resistance]
B: What is the โpatternโ for Resistance development for 2 drugs?
A:
[1ยฐ resistance is acquired at infection (drug resistant TB)]
vs.
[2ยฐ resistance - which develops during (SubOptimal TB tx)]
B: Risk of resistance development to 2 drugs= Risk of resistance development to each drug separately (their product)
A: Define [MDR-TB] MultiDrugResistance TB
B: Resistance to which of those eliminates ability to use [short 6 month course for TB]
A: Resistance to both Isoniazid and Rifampin
B: Rifampin
A: 4 Drug Regimen for TB Tx
B: Which drugs make up the Initial Phase
C: Which drugs make up the Continuation Phase
A: RIPE- Rifampin/ Isoniazid/ PyraZinAmide/ Ethambutol
B: Initial Phase = RIPE
C: Continuation Phase= ( R I )Ethambutol not needed if pt is not resistant to anything
A: Tx Course (Time) for TB
B: What 3 factors make this tx course successful
A: [2-3 times /week with DOT(Direct Observed Therapy)]
for 6 months โ>
B: Success if:
1) STRONG adherence
2) Sputum cultures convert in 2 mos.
3) No major cavitary lung dz
A: Define [XDR-TB] (eXtensively Drug Resistant TB)
B: What is the fundamental strategy to TB tx (2)
A: [XDR-TB] (eXtensively Drug Resistant TB) = Resistance to
- Isoniazid
- Rifampin
- Fluoroquinolone
- 1 injectable (-kacin)
B: Only use drugs never used in that pt before and use [2 drugs that are effective against ptโs particular TB strain]
LTBI (Latent TB Infection) [Treatment Regimens] (3)
- [9 mo. Isoniazid Monotherapy] = HIGHLY EFFECTIVE
- [4 mo. Rifampin daily therapy]= just as effective as #1
- [3 mo / 12 dose / once weekly / DOT: Isoniazid + Rifapentene]= just as effective as #1
[T or F]
[Leprosy Tx] is Similar to [TB Tx]
FALSE!!
Leprosytx is DIFFERENT THANTB Tx
Oral Iron Therapy
- A: Examples (3)*
- B: Route of Administration*
- Ferrous Sulfate
- Ferrous Gluconate
- Ferrous Fumarate
B: PO
Parenteral Iron Therapy
- A: Examples (3)*
- B: Route of Administration (2)*
- iron dextran
- iron sucrose
- iron gluconate
B: IM / IV
Vitamin B 12 Supplement
- A: Examples (3)*
- B: Route of Administration (3)*
- CyanoCobalamin = IM
- HydroxyCobalamin = IM
- [Oral Supplement (Oral only)]
EPO (Erythropoietin)
A: Route of Administration (2)
IV / [SubQ injection]
[Recombinant Human IL 11]
- A: Examples (1)*
- B: MOA*
- Oprelvekin
B: Promotes proliferation of [megakaryocytic progenitors] to INC [peripheral platelet count]
Oral Iron Therapy
A: MOA
B: Indication
A: INC Iron levels QUICKLYโ>[Anemia reversal in 1-3 months]
B: Iron Deficiency Anemia
Oral Iron Therapy
Side Effects (2)
- N/V
- Black Stools
Parenteral Iron Therapy
A: MOA
B: Indication (3)
A: INC Serum iron
B:
1) When Oral Iron is NOT tolerated
2) POST GI Resection
3) MalAbsorption syndromes
Parenteral Iron Therapy
Side Effects (4)
- Pain
- [Tissue Staining when IM]
- Anaphylaxis
- N/V
Deferoxamine / DeferaSirox
A: MOA
B: Indication
A: Iron Chelation (removal)
B: REVERSES Iron Toxicity